CClinicalTrials.gg
CompletedNCT01526915OCN/PRFUpdated Jan 2, 2020

Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates

An interventional study of Bone curettage + PRF and Bone curettage alone in Jawbone Osteochemonecrosis Induced by Bisphosphonates, sponsored by Centre Hospitalier Régional Metz-Thionville. Completed at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2011, registered Jan 2012).
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of our study is to assess, after tooth extraction, the efficacity of PRF in the prevention of healing delay and of jawbone osteochemonecrosis induced by bisphosphonates

Read the detailed description

Scientific Context Bisphosphonates (BP) work by slowing down bone remodelling. They are used in the management of different types of cancers and for the treatment of osteoporosis. Recent studies warned that this drug could produce adverse effects on jawbones .In December 2007, the AFSSAPS (French agency for the Sanitary Security of Health Products) alerted the health professionals about the risks of spontaneous or induced osteonecrosis following invasive odontological procedures on patients receiving BP. Prevalence of these osteonecrosis varies from 6% to 10% after surgical intervention. A healing delay estimated between 20 to 25% of cases frequently precedes the occurrence of osteochemonecrosis.

On the whole , the total rate of all complications amounts to 30%. We are extremely limited in terms of prevention or treatment of an OCN patient. We intend to study a biological autologous sediment obtained from a blood sample for its capacity to avoid these complications supervening. The collection of a coagulum called Platelet Rich Fibrin or PRF susceptible to provide the essential ingredients for the mucous membrane and the bone healing is obtained by centrifugation. This biomaterial rich in autologous fibrin is a concentrate of leukocytes, platelets and a number of factors favouring cicatrisation and immune response. Clinical applications are already well documented in orthopaedic, thoracic and cardiac surgeries and, also in dermatology. The use of PRF in dental surgery is more recent. Literature on this topic is very limited but these new techniques give rise to high hopes. Since February 2007,thanks to the classification as a medical treatment by the AFSSAPS, the PRF technique has been authorized.

Objectives To appraise after dental avulsion the PRF efficiency in preventing delay of cicatrisation and jawbone osteochemonecrosis induced by BP.

This efficiency will be assessed by a retroalveolar X-ray performed at each visit. The main criteria for evaluation is the discovery of cicatrisation delay at week 8 and/or osteochemonecrosis during the follow up.

Material and methods

Studied population: current or previous patients treated with BP and referred for a dental avulsion.

General experimental procedure: A prospective, longitudinal, multicentric, randomized open study. Patients will be randomized into two groups: dental avulsion only or dental avulsion and PRF. For both groups the initial management is surgical (bone curettage + PRF for the PRF group).The follow up is spread over one year with 10 visits. Each patient will undergo a clinical and photographic examination with a complete radiological check up(OPT),a standard biological blood test (blood count with haemogram (NFS) and a thorough calculation of the quantity of BP administered. The appearance of OCN or of any delay in cicatrisation will be documented by a histological biopsy, a bacteriological swab test and X-ray.

The requisite number of patients:

270 patients are required to validate the expected objectives in this study. Their recruitment will take place in 4 establishments: Metz-Thionville CHR (Regional Central Hospital) and three university teaching hospitals (CHU) Dijon, Nancy and Reims.

Total Duration of the study :

The estimated total duration will be 3 years: a 2 year recruitment with a 1 year follow-up.

Expected results and prospects To prove the interest of using PRF as a therapy able to prevent a delay in cicatrization or an OCN induced by BP.

02

Conditions studied

  • Jawbone Osteochemonecrosis Induced by Bisphosphonates

Keywords

  • PRF
  • PLATELET RICH FIBRIN
  • BISPHOSPHONATES
03

In context

Lead sponsor

Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 118 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient major(male or female)
  • Documented indication at the initial visit at day 0 (JO) for a maximum extraction of 3 teeth.
  • Treatment with nitrogenous or non-nitrogenous BP by intravenous injection or oral administration whichever the reason for this drug prescription:

    • on going BP treatment
    • patient having received a previous treatment with bisphosphonates (irrespective of the duration and withdrawal date of this treatment)
  • Patient having received the specific information letter regarding the study and having signed the clarified consent form.

Exclusion criteria

Exclusion Criteria:

  • Patient having a maxillary or mandibulary OCN at Day 0(JO)
  • Positive HIV serology at Day 0(for patients belonging to the PRF group)
  • Previous history of maxillo-cervico-facial radiotherapy
  • Patients with estimated survival expectancy shorter than one year
  • Lack of social security cover
  • Inability of the patient to respect the study follow-up
  • Patient having reached his/her majority and under tutelage,trusteeship or protection of the court
  • Patient whose diagnosis could not be revealed to him/her (especially when the patient or their family expressed this wish).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Bone curettage + PRF

    Bone curettage and PRF insertion

    Procedure: Bone curettage + PRF

  • Other
    Bone curettage alone

    Bone curettage without PRF insertion

    Procedure: Bone curettage alone

Interventions

  • ProcedureBone curettage + PRF

    Bone curettage and PRF insertion

  • ProcedureBone curettage alone

    Bone curettage without PRF insertion

06

What researchers measure

Primary outcomes

  1. Delay in cicatrisation at week 8

    Time frame: 8 weeks

  2. The appearance of osteochemonecrosis during the follow-up period

    Time frame: 1 year

Secondary outcomes

  1. The characteristics of the received BP treatment: starting date of ongoing treatment, accumulated dose, type of BP, administration route

    Time frame: 1 year

  2. The precise location of the extraction site according to the tooth classification number

    Time frame: 1 year

07

Study locations

5 sites
  • Chu de Dijon
    Dijon, 21033, France
  • Scm Bally Curien
    Maxeville, 54320, France
  • Chr Metz Thionville
    Metz, 57038, France
  • Chu de Nancy
    Nancy, 54035, France
  • Chu de Reims
    Reims, 51092, France
08

References and documents

Publications

  • Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3. PubMed 35866376 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01526915
Lead sponsor
Centre Hospitalier Régional Metz-Thionville
Responsible party
Sponsor
First posted
Feb 6, 2012
Start date
Sep 2011
Primary completion
Sep 2016
Completion
Jun 21, 2017
Last update
Jan 2, 2020

Study contacts

Eric GERARD, Dr
principal investigator · CHR Metz Thionville

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion